Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.76 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 11/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2093104 | 1.00 | PTGS1 (0.76) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL2095337 | 0.94 | PTGS1 (0.77) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL2088765 | 0.93 | PTGS1 (0.65) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL2088771 | 0.93 | PTGS1 (0.65) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL2088946 | 0.92 | PTGS1 (0.63) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL2088944 | 0.92 | PTGS1 (0.63) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL2094166 | 0.92 | PTGS1 (0.80) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL1047686 | 0.92 | PTGS1 (0.80) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL1047685 | 0.92 | PTGS1 (0.80) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL1044070 | 0.91 | PTGS1 (0.81) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | PTGS1 2872/4885SLC6A2 3591/4885SLC6A4 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.